Treatment Offered at Sarasota Memorial Hospital Shows Promising Results Treating COVID-19
Business
SRQ DAILY FRESHLY SQUEEZED CONTENT EVERY MORNING
THURSDAY APR 1, 2021 |
A monoclonal antibody cocktail developed by Regeneron cut the risk of hospitalization and death by 70 percent when given to high-risk Covid-19 patients in a large clinical trial, the drug maker announced last week. SMH was among 27 sites participating in the trial, which produced the most definitive evidence yet that the medicine can aid recovery early in the course of disease. “From August 2020 to January 2021, SMH did a lot of this groundbreaking research and many of our selfless, heroic patients participated as volunteers,” said Manuel Gordillo, MD, medical director of Infection Prevention & Control at SMH. “The results are very encouraging and a potential game changer.”
« View The Thursday Apr 1, 2021 SRQ Daily Edition
« Back To SRQ Daily Archive
